Dr. Philippe Chambon Joins Pharnext’s Board of Directors
January 02 2018 - 10:45AM
Business Wire
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA),
a biopharmaceutical company pioneering a new approach to the
development of innovative drugs based on the combination and
repositioning of known drugs, today announced its board of
directors has appointed Dr. Philippe Chambon as a new, independent,
non-executive member. He is replacing Jacques Attali for the
remainder of the term, until the Annual Shareholder’s meeting is
called to approve the 2018 financial statements.
Dr. Chambon, M.D, Ph.D., is a well-known healthcare professional
who has spent 22 years as a venture capital investor in the U.S.,
primarily focused on biopharmaceutical and digital health
companies. He led the creation of New Leaf Venture Partners as a
spin-off from the Sprout Group. As such, he served on numerous
boards of both private and public companies, including Auxilium
Pharmaceuticals (acquired by Endo), ePocrates Inc. (acquired by
AthenaHealth), Truveris and NxStage Medical (acquisition by
Fresenius Medical Care pending).
“We thank Jacques Attali for his unique and precious
contribution during the years he served on our board” said
Michel de Rosen, Chairman of Pharnext’s Board of Directors. “We
are delighted that Philippe is joining us. His experience,
expertise, and judgement are invaluable and will help Pharnext
reach the next level and deliver the innovative treatments we are
working on.”
Dr. Chambon added: “I am honored to have the opportunity
to work alongside Daniel, Michel and the whole Pharnext team. The
Company’s unique focus on the clear opportunity that drug
combinations represent has the potential to be truly
revolutionary.”
About PharnextPharnext is an advanced clinical-stage
biopharmaceutical company founded by renowned scientists and
entrepreneurs including Professor Daniel Cohen, a pioneer in modern
genomics. Pharnext has two lead products in clinical development.
PXT3003 is currently in an international Phase 3 trial for the
treatment of Charcot-Marie-Tooth disease type 1A and benefits from
orphan drug status in Europe and the United States. PXT864 has
generated positive Phase 2 results in Alzheimer’s disease. Pharnext
is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The
Company identifies and develops synergic combinations of
repositioned drugs at new optimal lower doses. These PLEODRUG™
offer several key advantages: efficacy, safety and intellectual
property, including several product or composition of matter
patents already granted. The Company is supported by a world-class
scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris
(ISIN code: FR0011191287).For more information, visit
www.pharnext.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180102005404/en/
PharnextXavier Paoli, +33 (0)1 41 09 22 30VP, Chief
Commercial Officercontact@pharnext.comorInvestor Relations
(Europe)MC Services AGAnne Hennecke, +49 211 529252
22anne.hennecke@mc-services.euorInvestor Relations
(U.S.)Stern Investor Relations, Inc.Matthew Shinseki, +1 212
362 1200matthew@sternir.comorFinancial Communication
(France)ActifinStéphane Ruiz, +33 (0)1 56 88 11
15sruiz@actifin.frorMedia Relations (Europe)ALIZE RPCaroline
CarmagnolAurore Gangloff+33 (0)1 44 54 36
64pharnext@alizerp.comorMedia Relations
(U.S.)RooneyPartnersMarion Janic, +1 212 223
4017mjanic@rooneyco.com
Pharnext (EU:ALPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharnext (EU:ALPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024